Navigation Links
Deadline Approaching for UCB Rheumatoid Arthritis Family Scholarship
Date:3/5/2010

ATLANTA, March 5 /PRNewswire/ -- Applications are being accepted until March 19, 2010 for the UCB Rheumatoid Arthritis Family Scholarship. These scholarships are for rheumatoid arthritis patients or their immediate family members. Winners are awarded up to $10,000 to continue their studies at an accredited institution of higher education in the U.S.

Requirements and an application can be found at http://www.reachbeyondra.com/scholarship. UCB awards more than 100 scholarships each year to patients suffering from a variety of diseases including epilepsy, Crohn's disease and rheumatoid arthritis.

About The UCB Rheumatoid Arthritis Family Scholarship

The program is designed for applicants of any age. Applicants must be legal and permanent residents of the United States; diagnosed with RA by a physician; seeking an associate's, undergraduate, or graduate degree or enrolled in a trade school educational program; enrolled in or awaiting acceptance from a United States-based institution of higher education; and a student who demonstrates academic ambition and embraces a way of life that overcomes the boundaries of living with RA.

About UCB

UCB (http://www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. UCB employs approximately 10,000 people in 40 countries.

Further Information:

Bert Kelly, UCB U.S. Communications & Public Relations, 770.970.8491, or e-mail: bert.kelly@ucb.com

This release was issued through eReleases(TM).  For more information, visit http://www.ereleases.com.

SOURCE UCB

Back to top

RELATED LINKS
http://www.ucb.com

'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mosquito Season Approaching: American Heartworm Society Reminds Pet Owners of Risk
2. CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis
3. Enbrel Will Remain Decision Resources Clinical Gold Standard Through 2018 for the Treatment of Rheumatoid Arthritis
4. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
5. New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis
6. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
7. SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
8. Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis
9. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
10. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
11. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... TORONTO , March 28, 2017 /PRNewswire/ ... full service medical device development firm, announced today that ... Toronto -based medical device industrial design and ... medtech companies throughout North America ... medical device talent spanning the design, engineering, regulatory, and ...
(Date:3/28/2017)... , March 28, 2017 Emosis SAS, ... new business entity, Emosis Ltd, headquartered in Tel Aviv ... novel assays complementing the mother company existing technology platform and test ... sales development of Emosis kits. ... This strategic move starts building Emosis international footprint. Emosis ...
(Date:3/28/2017)... 2017 RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... Patent Office (JPO) for the composition of matter ... for the treatment or prevention of fibrotic disorders, ... proliferative retinopathy (Japanese Patent #: 6060071).  This patent ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... City ... holidays (IBT World Travel Trends Report). As travelers visit both urban destinations, they ... temperatures, and prolonged sun exposure. In response, the outdoor industry has blurred the ...
(Date:3/28/2017)... ... , ... Alert Sentry Group LLC., a leader in the Personal Emergency Response ... and the iSAFE Plus. These iSAFE products are the most affordable and most advanced ... iSAFE Plus offer direct GPS Location and two-way calling with the push of a ...
(Date:3/28/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) is pleased ... new executive director. Mr. Still was selected through a careful months-long search by the ... is known to our members, has been a part of building the RBMA since ...
(Date:3/28/2017)... Vilnius, Lithuania (PRWEB) , ... March 28, 2017 ... ... identification technologies, today announced the release of two biometric time and attendance tracking ... Bio Attendance 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition ...
(Date:3/28/2017)... ... 28, 2017 , ... The Executives, Staff & Clients of MGE: Management Experts ... for Tots Literacy Campaign at their Semi-Annual Graduation and Fundraiser Event at MGE’s St. ... ranks at number 14 internationally in literacy. Statistically, a direct relation can be a ...
Breaking Medicine News(10 mins):